Olivera J. Finn

16.8k total citations · 4 hit papers
224 papers, 12.9k citations indexed

About

Olivera J. Finn is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Olivera J. Finn has authored 224 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Immunology, 115 papers in Molecular Biology and 77 papers in Oncology. Recurrent topics in Olivera J. Finn's work include Immunotherapy and Immune Responses (125 papers), Glycosylation and Glycoproteins Research (82 papers) and Monoclonal and Polyclonal Antibodies Research (73 papers). Olivera J. Finn is often cited by papers focused on Immunotherapy and Immune Responses (125 papers), Glycosylation and Glycoproteins Research (82 papers) and Monoclonal and Polyclonal Antibodies Research (73 papers). Olivera J. Finn collaborates with scholars based in United States, Germany and Italy. Olivera J. Finn's co-authors include Jan Schmielau, Richard S. Metzgar, Keith R. Jerome, Nieves Doménech, Anda Vlad, Michael S. Lan, Donna L. Barnd, John McKolanis, Robert Henderson and Paweł Ciborowski and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Olivera J. Finn

218 papers receiving 12.6k citations

Hit Papers

The Prioritization of Cancer Antigens: A National Cancer ... 2001 2026 2009 2017 2009 2001 2008 2003 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
    2009 1.1k citations Martin A. Cheever, James P. Allison et al. Clinical Cancer Research profile →
  2. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
    2001 716 citations Olivera J. Finn et al. profile →
  3. Cancer Immunology
    2008 620 citations Olivera J. Finn profile →
  4. Cancer vaccines: between the idea and the reality
    2003 503 citations Olivera J. Finn profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olivera J. Finn United States 60 8.3k 6.2k 5.1k 2.6k 931 224 12.9k
Gerd Ritter United States 62 9.2k 1.1× 5.6k 0.9× 5.4k 1.0× 1.8k 0.7× 812 0.9× 182 14.2k
Alan N. Houghton United States 72 8.9k 1.1× 7.2k 1.2× 7.7k 1.5× 2.3k 0.9× 1.1k 1.1× 208 16.8k
Özlem Türeci Germany 54 7.4k 0.9× 8.7k 1.4× 4.4k 0.9× 1.5k 0.6× 1.7k 1.8× 181 15.0k
Ivan D. Horak United States 62 5.7k 0.7× 4.8k 0.8× 3.9k 0.8× 1.8k 0.7× 1.4k 1.5× 205 14.0k
Karl Erik Hellström United States 51 6.5k 0.8× 3.1k 0.5× 3.8k 0.7× 2.2k 0.8× 1.1k 1.1× 172 11.8k
Steven J. Burakoff United States 71 9.7k 1.2× 7.7k 1.2× 3.5k 0.7× 2.4k 0.9× 930 1.0× 278 17.3k
Joseph B. Bolen United States 71 7.8k 0.9× 6.8k 1.1× 4.1k 0.8× 2.7k 1.1× 1.1k 1.1× 171 16.0k
Joy Burchell United Kingdom 60 5.0k 0.6× 9.3k 1.5× 2.5k 0.5× 3.9k 1.5× 603 0.6× 131 12.2k
Jeffrey A. Ledbetter United States 52 10.4k 1.3× 3.8k 0.6× 2.6k 0.5× 2.7k 1.0× 910 1.0× 118 14.8k
Roger M. Perlmutter United States 62 7.5k 0.9× 5.9k 1.0× 3.4k 0.7× 2.3k 0.9× 760 0.8× 125 13.2k

Countries citing papers authored by Olivera J. Finn

Since Specialization
Citations

This map shows the geographic impact of Olivera J. Finn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivera J. Finn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivera J. Finn more than expected).

Fields of papers citing papers by Olivera J. Finn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivera J. Finn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivera J. Finn. The network helps show where Olivera J. Finn may publish in the future.

Co-authorship network of co-authors of Olivera J. Finn

This figure shows the co-authorship network connecting the top 25 collaborators of Olivera J. Finn. A scholar is included among the top collaborators of Olivera J. Finn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivera J. Finn. Olivera J. Finn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stanton, Sasha E., Philip E. Castle, Olivera J. Finn, Shizuko Sei, & Leisha A. Emens. (2024). Advances and challenges in cancer immunoprevention and immune interception. Journal for ImmunoTherapy of Cancer. 12(3). e007815–e007815. 12 indexed citations
2.
Cameron, Cheryl, Vineet K. Raghu, Brian Richardson, et al.. (2024). Pre-vaccination transcriptomic profiles of immune responders to the MUC1 peptide vaccine for colon cancer prevention. Frontiers in Immunology. 15. 1437391–1437391.
3.
Ascierto, Paolo A., Lisa H. Butterfield, Olivera J. Finn, et al.. (2022). The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021. Journal of Translational Medicine. 20(1). 179–179. 2 indexed citations
4.
Beatty, Pamela, et al.. (2020). Myeloid derived suppressor cells in cancer, premalignancy and inflammation: A roadmap to cancer immunoprevention. Molecular Carcinogenesis. 59(7). 852–861. 10 indexed citations
5.
Minden, Jonathan S., et al.. (2020). Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention. Cancer Immunology Research. 8(8). 1027–1038. 10 indexed citations
6.
Ahmed, Yasmine, Michelle L. Miller, Claudia Coronnello, et al.. (2019). Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer. Cancer Immunology Research. 8(2). 167–178. 72 indexed citations
7.
8.
Kimura, Takashi, John McKolanis, Kazi Islam, et al.. (2012). MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study. Cancer Prevention Research. 6(1). 18–26. 186 indexed citations
9.
Meyskens, Frank L., Gregory A. Curt, Dean E. Brenner, et al.. (2011). Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic. Cancer Prevention Research. 4(3). 311–323. 36 indexed citations
10.
Yang, Qianting, Gang Li, Yibei Zhu, et al.. (2011). IL‐33 synergizes with TCR and IL‐12 signaling to promote the effector function of CD8+ T cells. European Journal of Immunology. 41(11). 3351–3360. 166 indexed citations
11.
Beatty, Pamela, Sowmya Narayanan, Jean Gariépy, Sarangarajan Ranganathan, & Olivera J. Finn. (2010). Vaccine against MUC1 Antigen Expressed in Inflammatory Bowel Disease and Cancer Lessens Colonic Inflammation and Prevents Progression to Colitis-Associated Colon Cancer. Cancer Prevention Research. 3(4). 438–446. 62 indexed citations
12.
Ryan, Sean O., Michael S. Turner, Jean Gariépy, & Olivera J. Finn. (2010). Tumor Antigen Epitopes Interpreted by the Immune System as Self or Abnormal-Self Differentially Affect Cancer Vaccine Responses. Cancer Research. 70(14). 5788–5796. 43 indexed citations
13.
Cheever, Martin A., James P. Allison, Andrea Stern Ferris, et al.. (2009). The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research. Clinical Cancer Research. 15(17). 5323–5337. 1050 indexed citations breakdown →
14.
Engelmann, Katja, Hongmei Shen, & Olivera J. Finn. (2008). MCF7 Side Population Cells with Characteristics of Cancer Stem/Progenitor Cells Express the Tumor Antigen MUC1. Cancer Research. 68(7). 2419–2426. 180 indexed citations
15.
16.
Vella, Laura A. & Olivera J. Finn. (2006). Innate and Adaptive Immunity in Lung Cancer. Novartis Foundation symposium. 279. 206–215. 5 indexed citations
17.
Carlos, Casey A., Hui Dong, O. M. Zack Howard, et al.. (2005). Human Tumor Antigen MUC1 Is Chemotactic for Immature Dendritic Cells and Elicits Maturation but Does Not Promote Th1 Type Immunity. The Journal of Immunology. 175(3). 1628–1635. 70 indexed citations
18.
Barratt‐Boyes, Simon M., Simon C. Watkins, & Olivera J. Finn. (1997). In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. The Journal of Immunology. 158(10). 4543–4547. 87 indexed citations
19.
Hand, Susan L., et al.. (1992). T CELL RECEPTOR Vβ GENE USAGE IN HLA-DR1-REACTIVE HUMAN T CELL POPULATIONS. Transplantation. 54(2). 357–367. 24 indexed citations
20.
Miceli, M. Carrie & Olivera J. Finn. (1989). T cell receptor beta -chain selection in human allograft rejection.. The Journal of Immunology. 142(1). 81–86. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerd Ritter Breakdown of academic impact, for papers by Alan N. Houghton Breakdown of academic impact, for papers by Özlem Türeci Breakdown of academic impact, for papers by Ivan D. Horak Breakdown of academic impact, for papers by Karl Erik Hellström Breakdown of academic impact, for papers by Steven J. Burakoff Breakdown of academic impact, for papers by Joseph B. Bolen Breakdown of academic impact, for papers by Joy Burchell Breakdown of academic impact, for papers by Jeffrey A. Ledbetter Breakdown of academic impact, for papers by Roger M. Perlmutter
Rankless by CCL
2026